Hodgkin's lymphoma survivors may have increased risk for cardiovascular disease
the ONA take:
According to a new study published online in JAMA Internal Medicine, researchers in the Netherlands have found that survivors of Hodgkin's lymphoma may be at a higher risk for cardiovascular diseases.
For the study, researchers evaluated 2,524 Dutch patients diagnosed with Hodgkin's lymphoma at younger than 51 years of age who had survived for 5 years after diagnosis. Patients had received mediastinal radiotherapy and anthracycline-containing chemotherapy.
Results showed that Hodgkin's lymphoma survivors had a 4-fold to 7-fold increased risk for coronary heart disease or heart failure 35 years or more after cancer treatment compared with the general population.
Researchers also found that mediastinal radiotherapy increased the risk for coronary heart disease, valvular heart disease, and heart failure, while those who received anthracycline-containing chemotherapy had a higher risk for valvular heart disease and heart failure as first events events versus patients who did not receive those treatments.
The findings suggest that "treating physicians and patients should be aware of the persistently increased risk of cardiovascular diseases throughout life, and the results of our study may direct guidelines for follow-up of patients with HL."
Survivors of Hodgkin's lymphoma may be at a higher risk for cardiovascular diseases.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|